3-O-methyldopa and motor fluctuations in Parkinson’s disease

Neurology

Volumn 37, Issue 5, 1987, Pages 856-859

  Fabbrini, G ^a   Juncos, J L ^a   Mouradian, M M ^a   Serrati, C ^a   Chase, T N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR SYSTEM; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; THERAPY;

ADMINISTRATION, ORAL; ADULT; AGED; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT; PARKINSON DISEASE; TYROSINE;

EID: 0023181117     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.37.5.856     Document Type: Article

References (27)

1. Fahn S. “On-off” phenomenon with levodopa therapy in parkin-sonism. Neurology 1974;24:431–441.
2. Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1976;1:292–296.
3. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkineon’s diseaae: relation to levodopa absorption and transport. N Engl J Med 1984;310:483–488.
4. Spencer SE, Wooten GF. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 1984;34:1105–1108.
5. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supemneitivity in Parkinson’s disease. Nature 1978;273:59–61.
6. Wade LA, Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975;17:131–136.
7. 14-dopa after selective inhibition of peripheral decarboxylase. J Pharmacol Exp Ther 1968;161:14–20.
8. Sharpless NS, McCann DS. Dopa and 3-O-methyldopa in cere-brospinal fluid of parkineonian patients during treatment with oral L-dopa. Clin Chim Acta 1971;31:155–169.
9. Bartholini G, Kuruma I, Pletscher A. 3-O-Methyldopa, a new precursor of dopamine. Nature 1971;230:533–534.
10. Reches A, Fahn S. 3-O-Methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 1982;12:267–271.
11. Gervas JJ, Hduradas V, Bazan E, Aguado EG, de Yebenes JG. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983;33:278–282.
12. Chase TN, Ng LKY. O-Methyldopa in parkinsonism. Neurology 1972;22:417.
13. Calne DB, Reid JL, Vakil SD. Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 1972;14:386–389.
14. Muenter MD, Dinapoli RP, Sharpless NS, Tyce GM. 3-O-Methyldopa, L-dopa and trihexyphenidyl in the treatment of Parkinson’s disease. Mayo Clin Proc 1973;48:173–183.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
16. Wagner J, Vitali P, Palfreyman MG, Zraika M, Huot S. Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxy-phenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high performance liquid chro-matography with electrochemical detection. J Neurochem 1982;38:1241–1254.
17. Muenter MD, Sharpless NS, Tyce GM. Plasma 3-O-methyldopa in L-dopa therapy of Parkinson’s disease. Mayo Clin Proc 1972;47:389–395.
18. Rivera-Calimlim L, Tandon D, Anderson F, Joynt R. The clinical picture and plasma levodopa metabolite profile of parkineonian nonresponders. Arch Neurol 1977;34:228–232.
19. Bartholini G, Kununa I, Pletscher A. The metabolic pathways of L-3-O-methyldopa. J Pharmacol Exp Ther 1972;183:65–72.
20. Weiss JL, Cohn CK, Chase TN. Reduction of catechol-O-meth-yltransferase activity by chronic L-dopa therapy. Nature 1971;234:218–219.
21. Baldessarini RJ. Inhibition of catechol-O-methyltnsferase by L-dopa and decarboxylase inhibitors. J Pharm Pharmacol 1972;24:78–79.
22. Reches A, Fahn S. Catechol-O-methyltransferase and Parkinson’s disease. Adv Neurol 1984;40:171–179.
23. Kremzner LT, Berl S, Mendoza M, Yahr MD. Cerebrospinal 5uid levels of dopa and 3-O-methyldopa in parkinsonism during treatment with L-dopa and MK-486. Adv Neurol 1973;2:79–89.
24. Barbeau A. The clinical physiology of side effects in long-term L-dopa therapy. Adv Neurol 1974;5:347–365.
25. Granerus AK. Factors influencing the occurrence of “on-off” symptom during long-term treatment with levodopa. Acta Med Stand 1978;203:75–85.
26. Shoulson I, Glaubiger GA, Chase TN. On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144–1148.
27. Lhermitte F, Agid Y, Feuerstein CL, et al. Mouvementa anormaux provoques par la L-dopa dane la maladie de Parkinson: correlation avec lee concentrations plasmatiques de dopa et de O-methyl-dopa. Rev Neurol (Paris) 1977;133:445–454.